Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin

European Journal of Cancer

Volumn 49, Issue 2, 2013, Pages 439-448

  Láng, István ^a   Köhne, Claus Henning ^b   Folprecht, Gunnar ^c   Rougier, Philippe ^d   Curran, Desmond ^e,h   Hitre, Erika ^a   Sartorius, Ute ^f   Griebsch, Ingolf ^f,i   Van Cutsem, Eric ^g  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^b KLINIKUM OLDENBURG   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e Omega Research   (Ireland)

^f MERCK KGAA   (Germany)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

ⁱ BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Cetuximab; FOLFIRI; KRAS wild type; Metastatic colorectal cancer; Quality of life

Indexed keywords

CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN;

ADULT; AGED; ARTICLE; ASYMPTOMATIC DISEASE; CANCER SURVIVAL; CLINICAL ASSESSMENT; COLORECTAL CANCER; CONTROLLED STUDY; DYSPNEA; FEMALE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; OPEN STUDY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; SOCIAL STATUS; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS; QUALITY OF LIFE; QUESTIONNAIRES; RAS PROTEINS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84872115684     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.08.023     Document Type: Article

References (25)

1. E. Van Cutsem, C.H. Kohne, and I. Lang Cetuximab plus irinotan, fluorouracil, and lecovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status J Clin Oncol 29 15 2011 2011 2019
2. E. Van Cutsem, C.H. Kohne, and E. Hitre Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 14 2009 1408 1417
3. C. Bokemeyer, I. Bondarenko, and A. Makhson Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 5 2009 663 671
4. C. Bokemeyer, I. Bondarenko, and J.T. Hartmann Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study Ann Oncol 22 7 2011 1535 1546
5. C.S. Karapetis, S. Khambata-Ford, and D.J. Jonker K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 17 2008 1757 1765
6. H.J. Au, C.S. Karapetis, and C.J. O'Callaghan Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial J Clin Oncol 27 11 2009 1822 1828
7. A.F. Sobrero, J. Maurel, and L. Fehrenbacher EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer J Clin Oncol 26 14 2008 2311 2319
8. N.R. Maisey, A. Norman, M. Watson, M.J. Allen, M.E. Hill, and D. Cunningham Baseline quality of life predicts survival in patients with advanced colorectal cancer Eur J Cancer 38 10 2002 1351 1357
9. F. Efficace, A. Bottomley, and C. Coens Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer? Eur J Cancer 42 1 2006 42 49
10. S.H. Park, M.S. Cho, and Y.S. Kim Self-reported health-related quality of life predicts survival for patients with advanced gastric cancer treated with first-line chemotherapy Qual Life Res 17 2 2008 207 214
11. C. Quinten, C. Coens, and M. Mauer Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials Lancet Oncol 10 9 2009 865 871
12. R. Mesia, F. Rivera, and A. Kawecki Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck Ann Oncol 21 10 2010 1967 1973
13. P.M. Fayers, N.K. Aaronson, K. Bjordal, D. Curran, and M. Groenvold EORTC QLQ-C30 scoring manual 2nd ed. 1999 EORTC Brussels
14. G. Verbeke, and G. Molenberghs Linear mixed models in practice 1997 Springer-Verlag New York
15. E.L.M.P. Kaplan Non parametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
16. V. Arndt, H. Merx, C. Stegmaier, H. Ziegler, and H. Brenner Quality of life in patients with colorectal cancer 1 year after diagnosis compared with the general population: a population-based study J Clin Oncol 22 23 2004 4829 4836
17. D. Curran, J. Giralt, and P.M. Harari Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab J Clin Oncol 25 16 2007 2191 2197
18. A.S. Coates, C. Hurny, and H.F. Peterson Quality-of-life scores predict outcome in metastatic but not early breast cancer. International Breast Cancer Study Group J Clin Oncol 18 22 2000 3768 3774
19. F. Efficace, and A. Bottomley Toward a clearer understanding of the prognostic value of health-related quality-of-life parameters in breast cancer J Clin Oncol 23 6 2005 1335 1336 author reply 1336
20. F.F. Kabbinavar, J.F. Wallace, and E. Holmgren Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer Oncologist 13 9 2008 1021 1029
21. L. Bennett, Z. Zhao, and B. Barber Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment Br J Cancer 105 10 2011 1495 1502
22. N.C. Tebbutt, K. Wilson, and V.J. Gebski Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study J Clin Oncol 28 19 2010 3191 3198
23. J. Tol, M. Koopman, and A. Cats Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer N Engl J Med 360 6 2009 563 572
24. S. Siena, M. Peeters, and E. Van Cutsem Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab Br J Cancer 97 11 2007 1469 1474
25. D. Odom, B. Barber, and L. Bennett Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab Int J Colorectal Dis 26 2 2011 173 181